Table 1 Baseline clinical characteristics according to patient cohort (Total N = 110)
Characteristic | MetS-MI- (n = 16) | MetS + MI- (n = 32) | MetS-MI + (n = 30) | MetS + MI + (n = 32) |
|---|---|---|---|---|
Age (years) | 42.3 ± 16.9 | 62.0 ± 10.2 | 60.1 ± 11.4 | 58.7 ± 14.8 |
Female sex (%) | 7 (44%) | 7 (23%) | 4 (14%) | 3 (9%) |
Caucasian (%) | 10 (62%) | 25 (81%) | 23 (79%) | 26 (79%) |
BMI (kg/m2) | 22.9 (21.7 – 24.0) | 32.5 (30.3 – 34.8) | 26.0 (24.5 – 27.5) | 30.4 (28.7 – 32.0) |
Waist circumference (cm) | 88.7 ± 25 | 119.9 ± 9 | 106.4 ± 14.3 | 116.0 ± 11 |
eGFR (ml/minute) | 94 ± 18 | 81 ± 23 | 78 ± 20 | 76 ± 21 |
Comorbidities (%) | ||||
Hypertension | 0 (0%) | 24 (77%) | 13 (45%) | 23 (70%) |
Diabetes | 0 (0%) | 14 (45%) | 2 (7%) | 14 (42%) |
Type I | 0 | 2 | 0 | 0 |
Type II | 0 | 12 | 2 | 14 |
Hyperlipidemia | 0 (0%) | 28 (90%) | 16 (55%) | 24 (73%) |
Smoking | 2 (12%) | 13 (42%) | 11 (38%) | 15 (46%) |
Prior PCI or CABG | 0 (0%) | 10 (32%) | 12 (41%) | 19 (58%) |
Blood profile | ||||
HgbA1c | NA | 0.08 (0.06 – 0.09) | 0.06 (0.05 – 0.07) | 0.07 (0.05 - 0.07) |
Total cholesterol | 4.9 (3.8 – 6.1) | 3.8 (3.4 – 4.3) | 4.2 (3.6 – 4.7) | 4.0 (3.5 – 4.5) |
Triglyceride | 1.2 (0.8 – 1.6) | 2.0 (1.6 – 2.5) | 1.3 (0.9 – 1.6) | 1.9 (1.3 – 2.4) |
HDL | 1.3 (0.8 – 1.7) | 0.9 (0.8 – 1.0) | 1.2 (1.0 – 1.3) | 0.9 (0.8 – 1.0) |
LDL | 3.1 (2.2 – 4.1) | 2.1 (1.6 – 2.5) | 2.5 (1.9 – 3.0) | 2.3 (1.8 - 2.7) |
Total cholesterol/HDL ratio | 4.1 (2.9 – 5.3) | 4.3 (3.9 – 4.8) | 3.9 (3.1 – 4.7) | 4.7 (3.8 – 5.6) |
Current medications | ||||
Aspirin (ASA) | 4 (25%) | 15 (46.9%) | 21 (70.0%) | 22 (68%) |
ACE inhibitor | 2 (12.5%) | 10 (31.3%) | 21 (70.0%) | 21 (65.7%) |
ARB | 0 (0%) | 9 (28.1%) | 3 (10%) | 8 (25%) |
Beta blocker | 5 (31.3%) | 26 (81.3%) | 24 (80.0%) | 25 (78.1%) |
Diuretic | 1 (6.3%) | 11 (34.4%) | 7 (23.3%) | 17 (53.1%) |
Fibrate | 0 (0%) | 1 (3.1%) | 1 (3.3%) | 2 (6.3%) |
Insulin | 0 (0%) | 1 (3.1%) | 0 (0%) | 2 (6.3%) |
Oral Hypoglycemic | 0 (0%) | 11 (34.4%) | 2 (6.7%) | 8 (25%) |
Statin | 2 (12.5%) | 24 (75%) | 16 (53.3%) | 19 (59.4%) |
Plavix | 0 (0%) | 4 (12.5%) | 6 (20.0%) | 7 (21.9%) |